New Research Aims to Optimize Therapy Against Onchocerciasis

Augustine R. Hong; Nicholas O. Opoku; Gary J. Weil; Eric M. Kanza; Michael E. Gyasi

New Research Aims to Optimize Therapy Against Onchocerciasis

Augustine R. Hong, Nicholas O. Opoku, Gary J. Weil, Eric M. Kanza, Michael E. Gyasi

Research output: Contribution to journal › Article › peer-review

Abstract

Onchocerciasis is a parasitic disease that is the second most common cause of infectious blindness in the world, affecting 25 million people, mostly in sub-saharan Africa. Mass drug administration (MDA) with ivermectin has been the mainstay of a successful international effort to reduce the burden of vision loss. Despite improvements in infection rates and blindness through MDA with ivermectin, adult worms are not killed or permanently sterilized by this drug and can live for greater than 10 years. Therefore, new treatments for onchocerciasis are critical to accelerating the rate of elimination of this blinding disease. Here we discuss an ongoing study of a new treatment for onchocerciasis.

Original language	English
Pages (from-to)	55-59
Number of pages	5
Journal	Missouri Medicine
Volume	119
Issue number	1
State	Published - Jan 1 2022

Cite this

@article{e5b6c158a28b42cfba8d88970a581654,

title = "New Research Aims to Optimize Therapy Against Onchocerciasis",

abstract = "Onchocerciasis is a parasitic disease that is the second most common cause of infectious blindness in the world, affecting 25 million people, mostly in sub-saharan Africa. Mass drug administration (MDA) with ivermectin has been the mainstay of a successful international effort to reduce the burden of vision loss. Despite improvements in infection rates and blindness through MDA with ivermectin, adult worms are not killed or permanently sterilized by this drug and can live for greater than 10 years. Therefore, new treatments for onchocerciasis are critical to accelerating the rate of elimination of this blinding disease. Here we discuss an ongoing study of a new treatment for onchocerciasis.",

author = "Hong, {Augustine R.} and Opoku, {Nicholas O.} and Weil, {Gary J.} and Kanza, {Eric M.} and Gyasi, {Michael E.}",

year = "2022",

month = jan,

day = "1",

language = "English",

volume = "119",

pages = "55--59",

journal = "Missouri Medicine",

issn = "0026-6620",

number = "1",

}

TY - JOUR

T1 - New Research Aims to Optimize Therapy Against Onchocerciasis

AU - Hong, Augustine R.

AU - Opoku, Nicholas O.

AU - Weil, Gary J.

AU - Kanza, Eric M.

AU - Gyasi, Michael E.

PY - 2022/1/1

Y1 - 2022/1/1

N2 - Onchocerciasis is a parasitic disease that is the second most common cause of infectious blindness in the world, affecting 25 million people, mostly in sub-saharan Africa. Mass drug administration (MDA) with ivermectin has been the mainstay of a successful international effort to reduce the burden of vision loss. Despite improvements in infection rates and blindness through MDA with ivermectin, adult worms are not killed or permanently sterilized by this drug and can live for greater than 10 years. Therefore, new treatments for onchocerciasis are critical to accelerating the rate of elimination of this blinding disease. Here we discuss an ongoing study of a new treatment for onchocerciasis.

AB - Onchocerciasis is a parasitic disease that is the second most common cause of infectious blindness in the world, affecting 25 million people, mostly in sub-saharan Africa. Mass drug administration (MDA) with ivermectin has been the mainstay of a successful international effort to reduce the burden of vision loss. Despite improvements in infection rates and blindness through MDA with ivermectin, adult worms are not killed or permanently sterilized by this drug and can live for greater than 10 years. Therefore, new treatments for onchocerciasis are critical to accelerating the rate of elimination of this blinding disease. Here we discuss an ongoing study of a new treatment for onchocerciasis.

UR - http://www.scopus.com/inward/record.url?scp=85146532451&partnerID=8YFLogxK

M3 - Article

C2 - 36033145

AN - SCOPUS:85146532451

SN - 0026-6620

VL - 119

SP - 55

EP - 59

JO - Missouri Medicine

JF - Missouri Medicine

IS - 1

ER -

New Research Aims to Optimize Therapy Against Onchocerciasis

Abstract

Other files and links

Fingerprint

Cite this